Literature DB >> 21201196

3-Phenyl-2-thioxo-1,3-thia-zolidin-4-one.

Feng-Xia Zhu, Jian-Feng Zhou, Gui-Xia Gong.   

Abstract

In the mol-ecule of the title compound, C(9)H(7)NOS(2), the heterocycle and the phenyl ring are oriented at a dihedral angle of 72.3 (1)°. Adjacent mol-ecules are connected through C-H⋯O inter-actions.

Entities:  

Year:  2008        PMID: 21201196      PMCID: PMC2959314          DOI: 10.1107/S1600536808030079

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For the synthesis of 3-phenyl­rhodanine, see: Brown et al. (1956 ▶). For the therapeutic properties of rhodanine-based mol­ecules, including anti­convulsant, anti­bacterial, anti­viral and anti­diabetic properties, see: Momose et al. (1991 ▶); HCV protease, Sudo et al. (1997 ▶); HCV NS3 protease, Sing et al. (2001 ▶); aldols reductase, Bruno et al. (2002 ▶); factor protease, Sherida et al. (2006 ▶).

Experimental

Crystal data

C9H7NOS2 M = 209.28 Monoclinic, a = 12.9941 (13) Å b = 5.6111 (6) Å c = 12.7271 (13) Å β = 93.847 (3)° V = 925.86 (17) Å3 Z = 4 Mo Kα radiation μ = 0.53 mm−1 T = 296 (2) K 0.20 × 0.15 × 0.05 mm

Data collection

Bruker APEXII diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2000 ▶) T min = 0.91, T max = 0.97 10918 measured reflections 1800 independent reflections 1146 reflections with I > 2σ(I) R int = 0.066

Refinement

R[F 2 > 2σ(F 2)] = 0.040 wR(F 2) = 0.080 S = 1.00 1800 reflections 118 parameters H-atom parameters constrained Δρmax = 0.25 e Å−3 Δρmin = −0.23 e Å−3 Data collection: APEX2 (Bruker, 2004 ▶); cell refinement: SAINT (Bruker, 2004 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEP-3 for Windows (Farrugia, 1997 ▶); software used to prepare material for publication: SHELXL97 and PLATON (Spek, 2003 ▶). Crystal structure: contains datablocks global, I. DOI: 10.1107/S1600536808030079/pk2120sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536808030079/pk2120Isup2.hkl Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C9H7NOS2F(000) = 432
Mr = 209.28Dx = 1.501 Mg m3
Monoclinic, P21/cMo Kα radiation, λ = 0.71073 Å
Hall symbol: -P 2ybcCell parameters from 1321 reflections
a = 12.9941 (13) Åθ = 3.1–21.1°
b = 5.6111 (6) ŵ = 0.53 mm1
c = 12.7271 (13) ÅT = 296 K
β = 93.847 (3)°Plate, yellow
V = 925.86 (17) Å30.20 × 0.15 × 0.05 mm
Z = 4
Bruker APEXII diffractometer1800 independent reflections
Radiation source: fine-focus sealed tube1146 reflections with I > 2σ(I)
graphiteRint = 0.066
Detector resolution: 8 pixels mm-1θmax = 26.0°, θmin = 1.6°
ω scansh = −14→15
Absorption correction: multi-scan (SADABS; Bruker, 2000)k = −6→6
Tmin = 0.91, Tmax = 0.97l = −15→15
10918 measured reflections
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.040Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.080H-atom parameters constrained
S = 1.00w = 1/[σ2(Fo2) + (0.0272P)2 + 0.2182P] where P = (Fo2 + 2Fc2)/3
1800 reflections(Δ/σ)max < 0.001
118 parametersΔρmax = 0.25 e Å3
0 restraintsΔρmin = −0.23 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
C10.35704 (19)0.8242 (4)0.64373 (18)0.0412 (6)
C20.2485 (2)0.5060 (4)0.58348 (17)0.0413 (6)
C30.32529 (19)0.5020 (4)0.50099 (19)0.0495 (7)
H3A0.29080.52310.43170.059*
H3B0.36160.35080.50240.059*
C40.20680 (17)0.7118 (4)0.74476 (17)0.0351 (6)
C50.13898 (18)0.8984 (4)0.74630 (18)0.0433 (6)
H50.13761.01400.69380.052*
C60.07285 (19)0.9134 (5)0.8263 (2)0.0478 (7)
H60.02621.03890.82750.057*
C70.0756 (2)0.7437 (5)0.90434 (19)0.0484 (7)
H70.03090.75490.95820.058*
C80.1438 (2)0.5586 (5)0.90295 (19)0.0512 (7)
H80.14550.44410.95590.061*
C90.21025 (19)0.5414 (4)0.82277 (18)0.0444 (6)
H90.25690.41580.82160.053*
N10.27190 (14)0.6844 (3)0.65849 (14)0.0364 (5)
O10.17588 (14)0.3754 (3)0.58706 (13)0.0541 (5)
S10.41400 (5)0.74161 (13)0.52991 (6)0.0566 (2)
S20.40143 (5)1.03944 (13)0.71931 (6)0.0583 (2)
U11U22U33U12U13U23
C10.0359 (15)0.0436 (15)0.0446 (14)0.0026 (12)0.0059 (11)0.0053 (12)
C20.0456 (16)0.0411 (15)0.0378 (13)0.0024 (13)0.0066 (12)0.0023 (12)
C30.0501 (16)0.0522 (17)0.0475 (14)0.0041 (14)0.0124 (12)−0.0048 (13)
C40.0342 (14)0.0356 (14)0.0362 (12)−0.0006 (11)0.0077 (11)−0.0010 (11)
C50.0440 (16)0.0407 (15)0.0458 (15)0.0024 (13)0.0069 (13)0.0055 (11)
C60.0403 (16)0.0461 (16)0.0577 (16)0.0089 (13)0.0089 (13)−0.0033 (13)
C70.0474 (16)0.0539 (17)0.0458 (14)−0.0049 (15)0.0182 (12)−0.0063 (14)
C80.0614 (18)0.0489 (16)0.0445 (15)−0.0046 (15)0.0125 (14)0.0097 (13)
C90.0497 (16)0.0370 (14)0.0472 (14)0.0093 (12)0.0090 (12)0.0044 (12)
N10.0359 (12)0.0356 (11)0.0386 (11)−0.0007 (9)0.0088 (9)−0.0003 (9)
O10.0594 (13)0.0506 (11)0.0532 (11)−0.0147 (10)0.0107 (9)−0.0059 (9)
S10.0465 (4)0.0673 (5)0.0588 (4)−0.0072 (4)0.0228 (3)−0.0061 (4)
S20.0511 (5)0.0561 (5)0.0682 (5)−0.0128 (4)0.0081 (4)−0.0131 (4)
C1—N11.379 (3)C4—N11.439 (3)
C1—S21.626 (3)C5—C61.378 (3)
C1—S11.733 (2)C5—H50.9300
C2—O11.198 (3)C6—C71.375 (3)
C2—N11.402 (3)C6—H60.9300
C2—C31.496 (3)C7—C81.366 (3)
C3—S11.793 (3)C7—H70.9300
C3—H3A0.9700C8—C91.384 (3)
C3—H3B0.9700C8—H80.9300
C4—C51.370 (3)C9—H90.9300
C4—C91.377 (3)
N1—C1—S2126.73 (18)C6—C5—H5120.3
N1—C1—S1110.68 (17)C7—C6—C5120.3 (2)
S2—C1—S1122.59 (15)C7—C6—H6119.9
O1—C2—N1123.1 (2)C5—C6—H6119.9
O1—C2—C3125.5 (2)C8—C7—C6120.2 (2)
N1—C2—C3111.4 (2)C8—C7—H7119.9
C2—C3—S1107.11 (17)C6—C7—H7119.9
C2—C3—H3A110.3C7—C8—C9120.0 (2)
S1—C3—H3A110.3C7—C8—H8120.0
C2—C3—H3B110.3C9—C8—H8120.0
S1—C3—H3B110.3C4—C9—C8119.5 (2)
H3A—C3—H3B108.5C4—C9—H9120.3
C5—C4—C9120.7 (2)C8—C9—H9120.3
C5—C4—N1120.3 (2)C1—N1—C2116.9 (2)
C9—C4—N1118.9 (2)C1—N1—C4124.14 (19)
C4—C5—C6119.4 (2)C2—N1—C4119.0 (2)
C4—C5—H5120.3C1—S1—C393.86 (12)
D—H···AD—HH···AD···AD—H···A
C5—H5···O1i0.932.513.410 (3)163.
C8—H8···O1ii0.932.463.386 (3)171.
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
C5—H5⋯O1i0.932.513.410 (3)163
C8—H8⋯O1ii0.932.463.386 (3)171

Symmetry codes: (i) ; (ii) .

  6 in total

1.  Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies.

Authors:  Sherida L Johnson; Dawoon Jung; Martino Forino; Ya Chen; Arnold Satterthwait; Dmitry V Rozanov; Alex Y Strongin; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Novel hepatitis C virus protease inhibitors: thiazolidine derivatives.

Authors:  K Sudo; Y Matsumoto; M Matsushima; M Fujiwara; K Konno; K Shimotohno; S Shigeta; T Yokota
Journal:  Biochem Biophys Res Commun       Date:  1997-09-18       Impact factor: 3.575

4.  Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.

Authors:  W T Sing; C L Lee; S L Yeo; S P Lim; M M Sim
Journal:  Bioorg Med Chem Lett       Date:  2001-01-22       Impact factor: 2.823

5.  Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

Authors:  G Bruno; L Costantino; C Curinga; R Maccari; F Monforte; F Nicoló; R Ottanà; M G Vigorita
Journal:  Bioorg Med Chem       Date:  2002-04       Impact factor: 3.641

6.  Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds.

Authors:  Y Momose; K Meguro; H Ikeda; C Hatanaka; S Oi; T Sohda
Journal:  Chem Pharm Bull (Tokyo)       Date:  1991-06       Impact factor: 1.645

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.